妊娠相关aHUS/补体介导TMA的病例叙述性综述
本文通过两例病例讨论妊娠相关aHUS/CM-TMA的诊断挑战与管理进展:一例孕早期诊断并自孕19周起使用依库珠单抗,检出CFI可能致病性变异,孕30周分娩健康婴儿;另一例产后严重HELLP综合征需血液透析,支持治疗后6个月补体激活指标仍异常但基因检测阴性。文章详述胎盘健康、胎儿解剖、补体激活、补体调节蛋白自身抗体及基因检测如何辅助临床诊断与抗补体治疗决策。
要点
- 妊娠可触发并暴露aHUS/CM-TMA,与妊娠期高血压疾病等TMA病因临床重叠,鉴别至关重要。
- 补体激活、补体调节蛋白自身抗体及基因检测有助于妊娠相关aHUS/CM-TMA的诊断与治疗指导。
- 病例显示依库珠单抗可用于妊娠期aHUS/CM-TMA,但需个体化评估。
核心结论
- 妊娠相关aHUS/CM-TMA诊断困难,需综合补体激活、自身抗体及基因检测与临床特征进行鉴别并指导抗补体治疗。
研究设计与样本
- 叙述性综述,通过2例妊娠相关aHUS/CM-TMA病例讨论诊断挑战与管理方法。
主要发现
- 病例1为30岁女性孕早期诊断aHUS/CM-TMA,自孕19周起接受依库珠单抗,基因检测发现CFI可能致病性变异,孕30周分娩健康婴儿。
- 病例2为22岁女性产后发生严重HELLP综合征需血液透析,支持治疗后好转,但产后6个月评估aHUS/CM-TMA的检查仍异常,提示持续补体激活,基因检测阴性。
关键数值与推荐
- 文中描述评估胎盘健康、胎儿解剖、补体激活、补体调节蛋白自身抗体及aHUS/CM-TMA基因检测,用于辅助临床诊断和指导管理包括抗补体治疗。
临床怎么用
- 妊娠期TMA鉴别应纳入aHUS/CM-TMA评估,结合补体激活标志、自身抗体和基因检测指导抗补体治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atypical hemolytic uremic syndrome is a complement-mediated thrombotic microangiopathy caused by uncontrolled activation of the alternative complement pathway in the setting of autoantibodies to or rare pathogenic genetic variants in complement proteins. Pregnancy may serve as a trigger and unmask atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy (aHUS/CM-TMA), which has severe, life-threatening consequences. It can be difficult to diagnose aHUS/CM-TMA in pregnancy due to overlapping clinical features with other thrombotic microangiopathy syndromes including hypertensive disorders of pregnancy. However, the distinction among thrombotic microangiopathy etiologies in pregnancy is important because each syndrome has specific disease management and treatment. In this narrative review, we discuss 2 cases to illustrate the diagnostic challenges and evolving approach in the management of pregnancy-associated aHUS/CM-TMA. The first case involves a 30-year-old woman presenting in the first trimester who was diagnosed with aHUS/CM-TMA and treated with eculizumab from 19 weeks' gestation. Genetic testing revealed a likely pathogenic variant in CFI. She successfully delivered a healthy infant at 30 weeks' gestation. In the second case, a 22-year-old woman developed severe postpartum HELLP syndrome, requiring hemodialysis. Her condition improved with supportive management, yet investigations assessing for aHUS/CM-TMA remained abnormal 6 months postpartum consistent with persistent complement activation but negative genetic testing. Through detailed case discussion describing tests assessing for placental health, fetal anatomy, complement activation, autoantibodies to complement regulatory proteins, and genetic testing for aHUS/CM-TMA, we describe how these results aided in the clinical diagnosis of pregnancy-associated aHUS/CM-TMA and assisted in guiding patient management, including the use of anticomplement therapy.
引用
- Che M, Moran SM, Smith RJ, et al. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy. Kidney Int. 2024. PMID: 38408703. doi:10.1016/j.kint.2023.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。